BSc, MBBS, PhD, FRCP
I am a consultant in medical oncology specialising in thoracic (lung) cancers, and was appointed at Chelsea and Westminster Hospital, London, in 2010.
I trained at University College and Middlesex School of Medicine, London, and graduated in anatomy and medicine in 1998. I specialised in medical oncology at Charing Cross and Hammersmith Hospitals, and during this time completed a PhD in tumour immunology, funded by Cancer Research UK. I went on to become a Clinical Lecturer in medical oncology at Imperial College London, supported by the Wellcome Trust and Academy of Medical Sciences, before being appointed to Chelsea & Westminster as a consultant.
I lead the lung cancer service at Chelsea & Westminster, and also lead the lung cancer group for the RM Partners Cancer Vanguard, which represents 3.5m patients in South and West London. At a national level I am part of the steering group for the British Thoracic Oncology Group steering committee. In addition to my work in lung cancer, I also have an interest in acute oncology, leading the Chelsea & Westminster acute oncology unit and sitting on the National Acute Oncology expert reference group.
I have presented my work at a number of national and international meetings. I have a great interest in teaching, and am an invited lecturer for various organisations including the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians.
My work at Chelsea and Westminster has been awarded the national Macmillan Innovation Excellence Award and short-listed for the Health Services Journal Clinical Services award.
I have an active lung cancer clinical trials portfolio, and am on the trial steering group and independent monitoring committees of a number of other studies. In addition I am a member of the National Cancer Research Institute (NCRI) lung cancer clinical study group.
My work has been published in a number of peer reviewed journals.
Tuthill MH et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene (2015); 34(16):2138-44.
Berardi R, et al. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget (2016); 7(18):26916-24
Baird R, et al. An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. Ecancermedicalscience. 2016 Jan 5;10:608. doi: 10.3332/ecancer.2016.608. eCollection 2016.
Viola P, et al., A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. J Thorac Oncol. 2016;11(7):1029-39.
Lebre MC, V et al. Synovial IL-21/TNF-producing CD4+ T cells induce joint destruction in rheumatoid arthritis by inducing matrix metalloproteinase production by fibroblast-like synoviocytes. J Leukoc Biol. 2016 Oct 12. pii: jlb.5A0516-217RR. [Epub ahead of print]
Berardi R, S et al. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget. 2016 Nov 15. (doi: 10.18632/oncotarget.13372)